✦ LIBER ✦

Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis

✍ Scribed by Fatma Ferda Verit; Iclal Geyikli; Pelin Yazgan; Ahmet Celik

Publisher: Springer
Year: 2006
Tongue: English
Weight: 192 KB
Volume: 274
Category: Article
ISSN: 0003-9128
DOI: 10.1007/s00404-006-0148-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of the effects of alendronate

Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis

✍ Mengu Sarioglu; Cigdem Tuzun; Zeliha Unlu; Canan Tikiz; Fatma Taneli; B. Sami. U 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 231 KB

Effect of alendronate on bone mineral de

Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis

✍ La-or Chailurkit; Wallaya Jongjaroenprasert; Sasithorn Rungbunnapun; Boonsong On 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 189 KB

Bone Mineral Density and Biochemical Mar

Bone Mineral Density and Biochemical Markers of Bone Turnover in Peri- and Postmenopausal Women

✍ V. De Leo; A. Ditto; A. la Marca; D. Lanzetta; C. Massafra; G. Morgante 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 226 KB

Effects of alendronate and risedronate o

Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis

✍ Aysegul Atmaca; Olcay Gedik 📂 Article 📅 2006 🏛 Springer Healthcare Communications 🌐 English ⚖ 279 KB

Dose–response study of denosumab on bone

Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis

✍ T. Nakamura; T. Matsumoto; T. Sugimoto; M. Shiraki 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 500 KB

Effects of denosumab on bone turnover ma

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat